Globus Medical, Inc. (NYSE:GMED) Given Consensus Rating of “Moderate Buy” by Analysts

Globus Medical, Inc. (NYSE:GMED) has been assigned an average rating of “Moderate Buy” from the sixteen analysts that are presently covering the firm, MarketBeat reports. Five equities research analysts have rated the stock with a hold recommendation, nine have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $103.75.

A number of analysts recently weighed in on GMED shares. Needham & Company LLC upped their price target on shares of Globus Medical from $114.00 to $117.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Royal Bank Of Canada cut their price objective on Globus Medical from $120.00 to $115.00 and set an “outperform” rating on the stock in a research report on Monday, July 13th. Wall Street Zen cut Globus Medical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Stifel Nicolaus reduced their price objective on Globus Medical from $95.00 to $80.00 and set a “hold” rating on the stock in a research note on Wednesday, July 8th. Finally, BMO Capital Markets started coverage on Globus Medical in a research report on Wednesday, July 8th. They issued an “outperform” rating and a $94.00 target price for the company.

Insider Buying and Selling

In related news, Director David D. Davidar sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the transaction, the director directly owned 510,175 shares of the company’s stock, valued at approximately $41,201,733. The trade was a 4.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 18.38% of the company’s stock.

Institutional Trading of Globus Medical

Hedge funds have recently made changes to their positions in the company. Elevation Wealth Partners LLC boosted its stake in shares of Globus Medical by 2,178.6% in the second quarter. Elevation Wealth Partners LLC now owns 319 shares of the medical device company’s stock valued at $25,000 after purchasing an additional 305 shares during the period. SBI Securities Co. Ltd. increased its stake in Globus Medical by 98.2% during the 4th quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock worth $29,000 after buying an additional 167 shares during the period. Advisory Services Network LLC acquired a new position in Globus Medical in the 3rd quarter worth $26,000. EverSource Wealth Advisors LLC lifted its holdings in Globus Medical by 74.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after buying an additional 197 shares in the last quarter. Finally, Larson Financial Group LLC boosted its position in Globus Medical by 83.4% in the 4th quarter. Larson Financial Group LLC now owns 532 shares of the medical device company’s stock valued at $46,000 after buying an additional 242 shares during the last quarter. Hedge funds and other institutional investors own 95.16% of the company’s stock.

Globus Medical Stock Down 0.8%

Shares of GMED stock opened at $75.48 on Thursday. The stock has a market cap of $10.25 billion, a price-to-earnings ratio of 17.55, a price-to-earnings-growth ratio of 1.57 and a beta of 0.95. Globus Medical has a fifty-two week low of $51.79 and a fifty-two week high of $101.40. The firm’s 50 day moving average price is $79.82 and its two-hundred day moving average price is $86.21.

Globus Medical (NYSE:GMED) last released its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.20. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The company had revenue of $759.85 million during the quarter, compared to the consensus estimate of $740.35 million. During the same period in the previous year, the firm earned $0.68 earnings per share. Globus Medical’s revenue for the quarter was up 27.0% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, equities analysts forecast that Globus Medical will post 4.74 EPS for the current fiscal year.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.